The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
By 2030, What Market Size Is The Biosimilar Contract Manufacturing Market Expected To Reach Based On Its 2026 Value?
The biosimilar contract manufacturing market has seen significant expansion in recent years. This market is set to expand from $9.94 billion in 2025 to $11.49 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 15.7%. The historical progression of this market can be linked to several factors, including the expiry of reference biologic patents, the early adoption of biosimilar development initiatives, an increase in contract manufacturing alliances, evolving regulatory directives for biosimilars, and a rising incidence of chronic diseases.
The biosimilar contract manufacturing market is projected to experience substantial expansion over the next few years. It is forecast to reach $20.35 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 15.4%. This growth throughout the forecast period stems from factors such as a rise in biosimilar approvals across international markets, mounting pressure to decrease the costs of biologic treatments, the expansion of biosimilar development pipelines, increasing investments in large-scale production facilities, and advances in process optimization technologies. Significant trends for the forecast period include an increase in the outsourcing of biosimilar manufacturing, a heightened demand for cost-effective production platforms, an expanding focus on analytical and quality control provisions, the broader adoption of mammalian cell-based manufacturing, and a strengthened commitment to regulatory compliance.
Access Your Free Sample Report For In-Depth Market Analysis:
https://www.thebusinessresearchcompany.com/sample.aspx?id=30215&type=smp
Which Factors Are Influencing The Growth Of The Biosimilar Contract Manufacturing Market?
The increasing incidence of diabetes is projected to boost the expansion of the biosimilar contract manufacturing market in the future. Diabetes prevalence describes the percentage of individuals within a population who have diabetes at a particular moment, indicating a continuous requirement for treatment and lifelong therapeutic needs. This rise in diabetes cases stems from more sedentary lifestyles and unhealthy eating habits, which contribute to obesity, insulin resistance, and a greater occurrence of type 2 diabetes. Biosimilar contract manufacturing aids in managing diabetes by facilitating the economical, large-scale creation of biosimilar insulin and associated biologics. This process guarantees consistent quality and adherence to regulations, thereby making sophisticated treatments more accessible to patients. Consequently, it improves the cost-effectiveness of treatments and broadens worldwide access to vital diabetes care. For example, in June 2024, data from the National Health Service, a UK-based government department, showed that 3,615,330 individuals registered with a general practitioner (GP) were diagnosed with non-diabetic hyperglycemia or pre-diabetes in 2023, representing an 18% rise from 3,065,825 cases in 2022. Thus, the rising occurrence of diabetes is propelling the growth of the biosimilar contract manufacturing market.
What Are The Main Segments Within The Biosimilar Contract Manufacturing Market Segment Structure?
The biosimilar contract manufacturing market covered in this report is segmented –
1) By Product Type: Monoclonal Antibodies, Insulin, Erythropoietin, Granulocyte Colony-Stimulating Factor, Other Product Types
2) By Service Type: Process Development, Analytical And Quality Control, Fill And Finish Operations, Packaging, Other Service Types
3) By Source: Mammalian, Non-mammalian
4) By Application: Oncology, Autoimmune Diseases, Blood Disorders, Growth Hormone Deficiency, Other Applications
5) By End-Use: Pharmaceutical Companies, Biotech Companies
Subsegments:
1) By Monoclonal Antibodies: Chimeric Monoclonal Antibodies, Humanized Monoclonal Antibodies, Fully Human Monoclonal Antibodies, Bispecific Monoclonal Antibodies
2) By Insulin: Rapid Acting Insulin, Short Acting Insulin, Intermediate Acting Insulin, Long Acting Insulin, Premixed Insulin
3) By Erythropoietin: Alpha Erythropoietin, Beta Erythropoietin, Darbepoetin Alfa, Continuous Erythropoietin Receptor Activators
4) By Granulocyte Colony-Stimulating Factor: Filgrastim, Pegfilgrastim, Lenograstim, Long Acting Granulocyte Colony-Stimulating Factor
5) By Other Product Types: Interferons, Interleukins, Fusion Proteins, Enzyme Therapeutics, Hormonal Biologics
What Trends Are Influencing The Evolution Of The Biosimilar Contract Manufacturing Market?
Major companies within the biosimilar contract manufacturing market are prioritizing the development of production facilities, such as mirrored single-use plants, to expedite technology transfer, scale-up processes, and commercial reliability. Mirrored single-use plants are defined as facilities comprising identical production suites that operate with disposable bioprocess equipment and unified digital systems, allowing for rapid changeovers, consistent quality across various sites, and a diminished risk of contamination. For example, in September 2025, Rezon Bio, a Poland-based contract development and manufacturing organization (CDMO), launched two mirrored-capability single-use biomanufacturing sites that cover the entire spectrum from cell line development to commercial GMP supply. This strategy facilitates quicker technology transfer and flexible scale-up for biosimilars with reduced downtime, simultaneously improving batch-to-batch consistency through standardized suites, integrated analytics, and logistics automation. Additionally, it lowers the total cost of ownership for sponsors by minimizing cleaning validation requirements, shortening development and manufacturing timelines, and de-risking expansion initiatives.
Who Are The Companies Participating In The Biosimilar Contract Manufacturing Market?
Major companies operating in the biosimilar contract manufacturing market are Thermo Fisher Scientific Inc., Biocon Limited, Lonza Group AG, Samsung Biologics Co. Ltd., WuXi Biologics (Cayman) Inc., Laboratorios Farmacéuticos Rovi S.A., Vetter Pharma-Fertigung GmbH & Co. KG, National Resilience Inc., Porton Pharma Solutions Co. Ltd., Syngene International Limited, Rentschler Biopharma SE, Boehringer Ingelheim International GmbH, Enzene Biosciences Ltd., Prestige Biologics Co. Ltd., Mabion S.A., HALIX B.V., BioConnection B.V., BioCina Pty Ltd, Mycenax Biotech Inc., Polpharma Biologics S.A.
Get The Full Biosimilar Contract Manufacturing Market Report:
Which Geographic Region Dominates The Biosimilar Contract Manufacturing Market?
North America was the largest region in the biosimilar contract manufacturing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the biosimilar contract manufacturing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Biosimilar Contract Manufacturing Market Report For Competitive Insights:
Browse Through More Reports Similar to the Global Biosimilar Contract Manufacturing Market 2026, By The Business Research Company
Biopharmaceuticals Contract Manufacturing Market Report 2026
Medical Device Contract Manufacturing Market Report 2026
Food Contract Manufacturing Market Report 2026
https://www.thebusinessresearchcompany.com/report/food-contract-manufacturing-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model